US Bancorp DE reduced its stake in shares of Evolent Health, Inc. (NYSE:EVH – Get Rating) by 48.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,761 shares of the technology company’s stock after selling 5,329 shares during the quarter. US Bancorp DE’s holdings in Evolent Health were worth $207,000 as of its most recent SEC filing.
→ The Next Big Crisis Is Here (From Porter & Company)
Several other hedge funds have also recently bought and sold shares of EVH. FMR LLC raised its stake in Evolent Health by 31.3% during the second quarter. FMR LLC now owns 4,509,709 shares of the technology company’s stock worth $138,493,000 after acquiring an additional 1,076,092 shares in the last quarter. Macquarie Group Ltd. grew its holdings in shares of Evolent Health by 145.9% during the second quarter. Macquarie Group Ltd. now owns 1,184,568 shares of the technology company’s stock worth $36,378,000 after purchasing an additional 702,899 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Evolent Health by 631.8% during the first quarter. Invesco Ltd. now owns 649,137 shares of the technology company’s stock worth $20,967,000 after purchasing an additional 560,438 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its holdings in shares of Evolent Health by 23,820.8% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 499,227 shares of the technology company’s stock worth $16,125,000 after purchasing an additional 497,140 shares during the last quarter. Finally, Victory Capital Management Inc. grew its holdings in shares of Evolent Health by 1,446.9% during the second quarter. Victory Capital Management Inc. now owns 455,393 shares of the technology company’s stock worth $13,986,000 after purchasing an additional 425,953 shares during the last quarter. 93.33% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several analysts have recently commented on the company. Piper Sandler increased their target price on Evolent Health from $44.00 to $51.00 in a report on Friday, January 6th. Truist Financial decreased their target price on Evolent Health to $32.00 in a report on Thursday, November 17th. BTIG Research decreased their target price on Evolent Health from $55.00 to $45.00 and set a “buy” rating on the stock in a report on Wednesday, October 12th. Canaccord Genuity Group decreased their target price on Evolent Health from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Wednesday, October 12th. Finally, StockNews.com cut Evolent Health from a “hold” rating to a “sell” rating in a report on Friday, November 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Evolent Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.50.
Evolent Health Price Performance
Shares of EVH opened at $31.19 on Friday. The company has a current ratio of 1.03, a quick ratio of 1.03 and a debt-to-equity ratio of 0.48. Evolent Health, Inc. has a 1 year low of $21.83 and a 1 year high of $39.78. The stock has a market cap of $3.16 billion, a P/E ratio of -207.92 and a beta of 1.56. The stock’s 50-day moving average price is $28.28 and its two-hundred day moving average price is $31.60.
Evolent Health (NYSE:EVH – Get Rating) last issued its earnings results on Wednesday, November 2nd. The technology company reported $0.52 earnings per share (EPS) for the quarter. Evolent Health had a positive return on equity of 8.83% and a negative net margin of 1.11%. The firm had revenue of $352.59 million for the quarter, compared to analysts’ expectations of $354.57 million. On average, equities analysts predict that Evolent Health, Inc. will post 0.61 earnings per share for the current year.
Insiders Place Their Bets
In other Evolent Health news, CEO Seth Blackley sold 75,000 shares of the firm’s stock in a transaction dated Monday, November 21st. The stock was sold at an average price of $26.79, for a total transaction of $2,009,250.00. Following the transaction, the chief executive officer now owns 422,037 shares in the company, valued at $11,306,371.23. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, Director Frank J. Williams sold 110,000 shares of the firm’s stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $27.15, for a total transaction of $2,986,500.00. Following the sale, the director now owns 626,479 shares of the company’s stock, valued at $17,008,904.85. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Seth Blackley sold 75,000 shares of the firm’s stock in a transaction dated Monday, November 21st. The stock was sold at an average price of $26.79, for a total value of $2,009,250.00. Following the sale, the chief executive officer now directly owns 422,037 shares in the company, valued at approximately $11,306,371.23. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 405,000 shares of company stock worth $11,333,950. Insiders own 4.20% of the company’s stock.
Evolent Health Profile
Evolent Health, Inc, a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evolent Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Evolent Health wasn’t on the list.
While Evolent Health currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: news.google.com
